Taysha Gene Therapies, Inc.
TSHA
Positions held
Your positionsTSHA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Taysha Gene Therapies is positioned in the rapidly growing gene therapy sector, which is expected to see significant advancements and investments in the coming years.
- The company's market cap stands at approximately $1.43 billion, indicating a strong investor interest.
- Despite recent challenges, Taysha's target mean price is set at $13.0, suggesting potential upside from current levels.
- The company has been facing significant operational challenges, with a current operating margin of -279.23%.
- In the most recent quarter, Taysha reported a net income loss of -46.639 million, continuing a trend of negative earnings.
- The stock has a strong sell signal with a score of -16.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $1.44B | Enterprise value | $1.04B | Trailing P/E | — | Forward P/E | -9.58 |
| PEG | — | Price / book | 6.00 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -27.9% |
| Profit margin | 0.0% | ROE | -47.1% | ROA | -23.8% | Debt / equity | 0.15 |
| Current ratio | 17.77 | Free cash flow | -$80.97M | Analyst recommendation | none | Mean target | $13.00 |
| 52w high | $7.30 | 52w low | $3.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $5.5M | $0.0M | $2.0M | — |
| Op margin | — | — | -516.0% | — | -1347.1% | — |
| Net income | -$46.6M | -$42.4M | -$27.9M | -$32.7M | -$26.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$50.8M | -$43.5M | -$28.3M | -$34.0M | -$26.8M | — |
- Operating margin expanded to -516%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M |
| Op margin | -1130.6% | -1039.5% | -461.9% | -5037.1% |
| Net income | -$109M | -$89.3M | -$112M | -$166M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$110M | -$86.6M | -$71.4M | -$126M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
2026-10-02 · Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-17 · Wolfe Research Initiates Taysha Gene Therapies at Outperform
2026-09-07 · These 3 Risky Stocks Could Be Sitting on 100% Upside
2026-09-04 · Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-18 · Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
2026-08-13 · Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
2026-08-12 · Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary
2026-08-12 · Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
2026-08-12 · Taysha Gene Therapies Q2 Earnings Call Highlights
2026-08-11 · Taysha Gene Therapies Q2 Loss Widens
Price (daily)
Full chart · RSI · MACD · patterns